This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
Herceptin SC is a subcutaneous formulation that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of Herceptin to be rapidly dispersed and absorbed over a greater area.
Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) and HER2 positive early breast cancer (EBC)
If a patient becomes pregnant while receiving Herceptin, or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at
M-PK-00001196
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.